leukemogenic


Also found in: Dictionary.

leu·ke·mo·gen·ic

(lū-kē'mō-jen'ik),
Pertaining to the causation, induction, and development of leukemia; manifesting the ability to cause leukemia.

leukemogenic

adjective Causing leukemia, an acute or chronic disease characterized by an abnormal number of leukocytes or the presence of abnormal leukocytes

leu·ke·mo·gen·ic

(lū-kē'mō-jen'ik)
Pertaining to the causation, induction, and development of leukemia; manifesting the ability to cause leukemia.
Synonym(s): leukaemogenic.
References in periodicals archive ?
A vast majority of patients with acute myeloid leukemia (AML) exhibit down-regulation of KLF4 expression, which is directly associated with leukemogenic events, or the onset of leukemia.
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
Dameshek hesitated to use a potentially dangerous radioactive material in an individual with a relatively long lifespan (2) and questioned whether the acute leukemic states that have occurred in some cases are due to the potentially leukemogenic drug P32 or are associated with the natural history of polycythemia.
Defective DNA-mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia.
Animal studies (5,7) suggest that the fusion proteins alone are not able to induce leukemia and that additional genetic alterations are required for leukemogenic transformation.
Leukemogenic potential may need to be considered as part of the risks-and-benefits deliberation when recommending treatment for localized prostate cancer," he said.
For example, if there is a desire to determine whether benzene has been leukemogenic (i.
In addition, the region of MLL that breaks and joins to other genes in leukemogenic translocations is remarkably conserved at just over 8 kilobases (kb) in a central region of the gene.
Select the function that is NOT associated with leukemogenic mechanisms in CML.
The Phase 2 study will be conducted at multiple centers in North America and is expected to enroll up to 60 patients with secondary AML (patients with antecedent myelodysplastic syndrome or prior exposure to leukemogenic therapy).
Youngsters treated with leukemogenic chemotherapy regimens need yearly complete blood cell count surveillance for 10 to 15 years after treatment.
In MLL, chromosomal rearrangements of the MLL gene result in aberrant recruitment of the DOT1L HMT, which drives the expression of genes that are leukemogenic in the affected patients.